Effect of Interferon Gamma as a Treatment for Post-aggressive Immunosuppression in Intensive Care Units, a Randomized Bayesian Double-blind Controlled Trial Versus Placebo

Key facts

Sponsor

Assistance Publique - Hôpitaux de Paris

Principal Investigator

Charles De ROQUETAILLADE, MD

APHP(ASSISTANCE PUBLIQUE DES HOPITAUX DE PARIS

Intervention

Interferon Gamma 1-b(drug)

Enrollment

170 enrolled

Eligibility

18 years · All sexes

Timeline

2026 – 2028

Study locations (2)

• Dr de Roquetaillade, Paris, France
• Pr Dépret, Paris, France

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for C syndrome

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE2NCT07283900
  Ascorbate in Myelodysplastic Syndrome
  Prajwal Dhakal
• RECRUITINGPHASE2NCT07505745
  MOTS-c for Improving Insulin Sensitivity in Adults With Prediabetes and Overweight/Obesity
  Hudson Biotech
• RECRUITINGPHASE4NCT06865885
  LDL-C Optimization Using Inclisiran in Patients in Which Drug-Drug Interactions Limit LDL Lowering
  University of California, San Diego
• ACTIVE NOT RECRUITINGNCT06797609
  Comparing the Performance of Serum Creatinine and Cystatin C-based GFR Estimations in Predicting Directly Measured GFR in Patients With or Without Nephrotic Syndrome
  Mario Negri Institute for Pharmacological Research
• RECRUITINGNANCT06528639
  A Clinical Study on Exercise Guided by CPET to Reduce the Risk of Metabolic Cardiovascular Diseases（C-MET Trial）
  Peking University Third Hospital
• ACTIVE NOT RECRUITINGNANCT05497388
  Efficacy of Serious Game Interventions on HCV Education for HIV Patients
  National Taiwan University Hospital
• RECRUITINGNANCT05390424
  Screening for Hepatitis B, Hepatitis C and AIDS Viruses Using Dried Blood Spot
  University Hospital, Rouen
• RECRUITINGPHASE1, PHASE2NCT04742634
  Pre-emptive Therapy With DEC-C to Improve Outcomes in MDS Patients With Measurable Residual Disease Post Allogeneic Hematopoietic Cell Transplant
  Washington University School of Medicine

See all trials for C syndrome →